CLASSIFIED: Deep Cut: Single Dose DMT Treats Depression

🛸 CLASSIFIED BRIEFING 🛸

The Liminal Report - Pilot Episode

CLEARANCE LEVEL: ANOMALOUS

DEEP CUT: SINGLE DOSE DMT TREATS DEPRESSION

Imperial College study shows 25-minute psychedelic session provides months of relief

The Intelligence Brief

A clinical trial of 34 people with treatment-resistant depression found that a single 21.5mg dose of DMT (dimethyltryptamine) infused intravenously over 10 minutes, combined with psychotherapy, produced rapid and lasting antidepressant effects persisting 3-6 months. DMT is the active ingredient in ayahuasca. The trip lasts ~25 minutes (shorter but more intense than psilocybin).

Participants reported encounters with "otherworldly beings," dissolution of self, and altered sense of time and space. Dr David Erritzoe (ICL): likens the effect to "redistributing snow on a mountain" — flattening entrenched neural pathways so new ones can form.

This follows positive psilocybin trials that may lead to UK approval this year. 5-MeO-DMT (toad venom variant) has separately been shown to produce brain states identical to advanced meditation in a Tibetan Buddhist lama with 54,000+ hours of meditation experience.

Key Evidence

• Published in Nature Medicine, February 16, 2026
• Phase II clinical trial: 34 participants with treatment-resistant depression
• Single 21.5mg dose, 10-minute IV infusion
• Effects lasting 3-6 months
• Combined with psychological support
• Follows successful psilocybin trials

The Sceptic's Case

Small sample size limits statistical power. Industry funding (Cybin UK) may introduce bias. Long-term safety profile remains unknown. The "otherworldly beings" experiences could be neurochemical artifacts rather than genuine encounters. More research needed before clinical approval.

The Anomalist's Case

100 million people worldwide have treatment-resistant depression — conventional treatments have failed them. If validated, a single 25-minute session could provide months of relief. The consistency of "entity encounter" reports across cultures and individuals suggests these experiences tap into fundamental aspects of consciousness that mainstream psychology doesn't recognize.

Caveats & Limitations

Small sample size requires larger trials for validation. Industry funding source. Long-term effects unknown. Mechanism of action not fully understood. Integration with existing mental health frameworks needed.